 "Allergan")
AbbVie Inc. agreed to pay $63 billion for rival drugmaker Allergan Plc, the latest merger in an industry where some of the biggest companies have been willing to pay a big premium to resolve questions about their growth prospects.
The price tag caused some heartburn on Wall Street, with AbbVie declining as much as 16% to $66 at 1:38 p.m. in New York, putting the stock on course for its worst single-session drop since the drugmaker was spun off from former parent Abbott Laboratories.
Allergan shares climbed as much as 30%. AbbVie will pay
The price tag caused some heartburn on Wall Street, with AbbVie declining as much as 16% to $66 at 1:38 p.m. in New York, putting the stock on course for its worst single-session drop since the drugmaker was spun off from former parent Abbott Laboratories.
Allergan shares climbed as much as 30%. AbbVie will pay
